ReviewQJM : monthly journal of the Association of Physicians2014
Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis.
Review in QJM : monthly journal of the Association of Physicians, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 73 citations in OpenAlex.
- Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.Scientific reports · 2021Trial
- Article
- LGMN regulates endothelial-to-mesenchymal transition via the p38 MAPK pathway to promote pulmonary fibrosis.Functional & integrative genomics · 2026Article
- Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis.JCI insight · 2026Article
- Idiopathic pulmonary fibrosis from a multiscale mechanobiology perspective: Mechanisms and future therapeutic prospects.iScience · 2026Review
- Absolute and lung volume-normalized deep learning-derived pulmonary vascular measures in idiopathic pulmonary fibrosis: distinct clinical associations and the role of lung volume in prognosis.Frontiers in medicine · 2026Article
- Exploring sarcoidosis via nailfold capillaroscopy: A window into the disease's microvascular landscape.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- von Willebrand Factor Deficiency Inhibits Endothelial-to-Mesenchymal Transition to Attenuate Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2025Article
- Antiphospholipid antibodies and subclinical interstitial lung disease in the MESA cohort.Respiratory research · 2025Observational
- Development of novel technology for the visualization and quantitation of angiogenesis and the alveolar-capillary network in a mouse model of fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- The Role of Nailfold Videocapillaroscopy in the Diagnosis and Monitoring of Interstitial Lung Disease Associated with Rheumatic Autoimmune Diseases.Diagnostics (Basel, Switzerland) · 2025Review
- New perspectives on the progression of pulmonary fibrosis: the cascade from aberrant microvascular endothelial cell activation to fibrosis.Frontiers in medicine · 2025Review
- Vascular involvement in idiopathic pulmonary fibrosis.ERJ open research · 2024Review
- Harnessing Advanced Machine Learning Techniques for Microscopic Vessel Segmentation in Pulmonary Fibrosis Using Novel Hierarchical Phase-Contrast Tomography Images.Methods of information in medicine · 2024Article
- Relationship between nailfold capillaroscopy findings and the etiology and prognosis of interstitial lung disease.Clinical rheumatology · 2024Article
- Lung injury-induced activated endothelial cell states persist in aging-associated progressive fibrosis.Nature communications · 2024Article
- Advancements in preclinical human-relevant modeling of pulmonary vasculature on-chip.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024Review
- Optimized quantitative mapping of cardiopulmonary oscillations using hyperpolarizedMagnetic resonance in medicine · 2024Article
- Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects.American journal of stem cells · 2024Review
- Vascular Contribution to Lung Repair and Fibrosis.American journal of respiratory cell and molecular biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrosing interstitial pneumonia of unknown aetiology that usually leads to respiratory failure and death within 5 years of diagnosis. Alveolar epithelial cell injury, disruption of alveolar capillary membrane integrity and abnormal vascular repair and remodelling have all been proposed as possible pathogenic mechanisms. This review summarizes our current knowledge of the abnormalities in vascular remodelling observed in IPF and highlights several of the cytokines thought to play a pathogenic role, which may ultimately prove to be future therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.